ES2428665B1 - Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization - Google Patents
Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization Download PDFInfo
- Publication number
- ES2428665B1 ES2428665B1 ES201230664A ES201230664A ES2428665B1 ES 2428665 B1 ES2428665 B1 ES 2428665B1 ES 201230664 A ES201230664 A ES 201230664A ES 201230664 A ES201230664 A ES 201230664A ES 2428665 B1 ES2428665 B1 ES 2428665B1
- Authority
- ES
- Spain
- Prior art keywords
- composition
- inflammation
- prevention
- treatment
- oxidative stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/26—Organic compounds containing oxygen
- C11D7/261—Alcohols; Phenols
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/26—Organic compounds containing oxygen
- C11D7/267—Heterocyclic compounds
Abstract
Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular.#La presente invención se refiere al uso de la quercetina (QCT) o de una composición que comprende QCT y al menos otro compuesto polifenólico, preferiblemente resveratrol (RES), para el tratamiento y/o prevención de lesiones o enfermedades que cursan con inflamación, estrés oxidativo y/o neovascularización ocular, preferiblemente del segmento anterior, más preferiblemente de la superficie ocular y aun más preferiblemente del epitelio corneal. La invención también se refiere al uso de la QCT y de dicha composición como agente antimicrobiano, antioxidante y antiinflamatorio en soluciones de limpieza y mantenimiento de lentes de contacto.Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization. # The present invention relates to the use of quercetin (QCT) or a composition comprising QCT and at least one other polyphenolic compound , preferably resveratrol (RES), for the treatment and / or prevention of lesions or diseases that occur with inflammation, oxidative stress and / or ocular neovascularization, preferably of the anterior segment, more preferably of the ocular surface and even more preferably of the corneal epithelium. The invention also relates to the use of QCT and said composition as an antimicrobial, antioxidant and anti-inflammatory agent in contact lens cleaning and maintenance solutions.
Description
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230664A ES2428665B1 (en) | 2012-05-04 | 2012-05-04 | Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization |
PCT/ES2013/070279 WO2013164512A2 (en) | 2012-05-04 | 2013-05-06 | Composition for use in the treatment and/or prevention of inflammation, oxidative stress and ocular neovascularization |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230664A ES2428665B1 (en) | 2012-05-04 | 2012-05-04 | Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2428665A1 ES2428665A1 (en) | 2013-11-08 |
ES2428665B1 true ES2428665B1 (en) | 2014-10-01 |
Family
ID=48700616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201230664A Active ES2428665B1 (en) | 2012-05-04 | 2012-05-04 | Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2428665B1 (en) |
WO (1) | WO2013164512A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2941841C (en) | 2014-03-28 | 2021-08-17 | Hortus Novus Srl | Compositions based on saffron for the prevention and/or treatment of degenerative eye disorders. |
CN106659698A (en) | 2014-09-19 | 2017-05-10 | 霍图斯诺伟司有限责任公司 | Compositions based on saffron for the prevention and/or treatment of corneal dystrophies. |
IT202200002108A1 (en) | 2022-02-07 | 2023-08-07 | Indena Spa | QUERCETIN-BASED COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004517631A (en) * | 2001-01-17 | 2004-06-17 | ヨウン メー パク | Method for inhibiting gene expression of vascular endothelial growth factor and erythropoietin by quercetin |
US20030133945A1 (en) * | 2002-01-11 | 2003-07-17 | Farley Michael Donald | Natural food supplement |
US20060127505A1 (en) | 2002-01-16 | 2006-06-15 | David Haines | Anti-inflammatory formulations |
JP2006501308A (en) * | 2003-01-09 | 2006-01-12 | ドナルド ファーリー,マイケル | Improving immune function |
US20060111318A1 (en) * | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
US20050163873A1 (en) * | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
US20050220907A1 (en) * | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Implanted medical devices with anti-inflammatory coatings |
WO2005099721A2 (en) * | 2004-04-15 | 2005-10-27 | The Regents Of The University Of California | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
US20070212395A1 (en) * | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
DE602006013787D1 (en) * | 2006-03-28 | 2010-06-02 | Epitech Group Srl | A pharmaceutical composition for the treatment of pathologies caused by the general immune response |
WO2008016095A1 (en) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
CA2670409A1 (en) * | 2006-11-22 | 2008-05-29 | Ocumedic Aps | Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye |
WO2011057183A1 (en) * | 2009-11-06 | 2011-05-12 | Alcon Research, Ltd. | Nutritional supplements for relief of dry eye |
-
2012
- 2012-05-04 ES ES201230664A patent/ES2428665B1/en active Active
-
2013
- 2013-05-06 WO PCT/ES2013/070279 patent/WO2013164512A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
ES2428665A1 (en) | 2013-11-08 |
WO2013164512A2 (en) | 2013-11-07 |
WO2013164512A3 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2524320T3 (en) | Composition for the prevention or treatment of disease associated with thrombus or embolus | |
CL2012001583A1 (en) | Ophthalmic preparation comprising: a) povidone iodine, b) a cooling agent and c) one or more of camphor, borneol, lubricant, emollient, steroidal anti-inflammatory and non-steroidal anti-inflammatory; and its use for the treatment and / or prophylaxis of an eye disorder or infection. | |
CO2017004715A2 (en) | Methods and formulations to treat vascular eye diseases | |
CL2017002526A1 (en) | Use of formyl 2 peptide receptor agonists to treat inflammatory eye diseases (divisional application No. 2485-2015) | |
CL2019001079A1 (en) | Methods for using indazole-3-carboxamides and their use as inhibitors of the wnt / b-catenin signaling pathway. | |
CL2017003138A1 (en) | Tricyclic derivative compound, method of preparation thereof and pharmaceutical composition comprising it. | |
UY32989A (en) | CONCENTRATED THERAPEUTIC PHOSPHOLIPID COPOSITIONS | |
BR112014008789A2 (en) | prevention and treatment of eye conditions | |
MY197845A (en) | Pharmaceutical composition | |
CL2013000713A1 (en) | Pirazin-2-carbonyl-imino-1,3,8-triaza-spiro- [4.5] -decan-substituted compounds, epithelial sodium channel blockers (enac); pharmaceutical composition that includes them; prevention or treatment method; and its use to treat a disease or condition mediated by blockade of the epithelial sodium channel. | |
ECSP18012793A (en) | COMPOSITION AND PRODUCTS INCLUDING SENESCENT CELLS FOR USE IN TISSUE REGENERATION | |
BR112012028451A2 (en) | topical composition of povidone iodine | |
BR112018003892A2 (en) | Pharmaceutical composition and method for reducing fat | |
ES2428665B1 (en) | Composition for use in the treatment and / or prevention of inflammation, oxidative stress and ocular neovascularization | |
CL2014003503A1 (en) | Pharmaceutical composition for intramammary use comprising a phosphonic acid and at least one antimicrobial agent; and use for the treatment or prevention of mastitis in non-human mammals. | |
BR112014010376A2 (en) | medicament for treating anterior eye disease comprising rebamipide and a tear retention agent | |
UY32758A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPTICAL, NASAL OR OPHTHAL INFECTIONS | |
CO7240418A2 (en) | Dressing with a prolonged release of active agents | |
BR112012028437A2 (en) | ophthalmic solution and method for treating glaucoma or ocular hypertension | |
BR112012022074A2 (en) | A composition comprising as active ingredients l-carnitine in combination with hydroxyquinurenine-o-beta-dl-glycoside for the prevention and / or treatment of eye conditions due to ultraviolet radiation | |
BR112015005942A2 (en) | cynara scolymus extracts, coffea spp. and olea europaea for treatment of metabolic syndrome | |
CO7131368A2 (en) | (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) -nifuratel | |
PE20150721A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING GEMIGLIPTIN AND METFORMIN, AND METHOD FOR THEIR PREPARATION | |
NI201900063A (en) | AROMATIC AMIDES OF CARBOXYLIC ACID | |
UY33153A (en) | TYPICAL OPTIMAL FORMULATION OF PEPTIDES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2428665 Country of ref document: ES Kind code of ref document: B1 Effective date: 20141001 |